Is Stryker Corporation (SYK) a Buy, Sell, or Hold?
Stryker Corporation
NYSE:SYK
$311.07001 USD
-$20.38 (-6.15%)
- Volume
- 4.05M
- Average Volume
- 2.7M
- Market Capitalization
- $119.25B
- P/E Ratio
- 35.63
- Dividend Yield
- 1.12%
- Price Target
- $378.00
- Year High
- $404.87
- Year Low
- $281.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.39
- Current Ratio
- $2.11
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Kevin A. Lobo |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Current Symbol | SYK |
| CUSIP | 863667101 |
| CIK | 0000310764 |
| Web | https://www.stryker.com |
| Phone | 269 385 2600 |
| Currency | USD |
| Employees | 56000 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.66 |
| Payout Ratio | 0.39 |
| Current Ratio | 2.11 |
| Quick Ratio | 1.25 |
| Cash Ratio | 0.46 |
Sales & Book Value
| Annual Sales | $25.12B |
| Price / Sales | 4.72 |
| Cash Flow | 11.94 |
| Price / Cash Flow | 26.09 |
| Price / Book | 5.18 |
Price Target and Rating
| Average Stock Price Forecast | $378.00 |
| High Stock Price Forecast | $465.00 |
| Low Stock Price Forecast | $315.00 |
| Forecast Upside/Downside | -17.71% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 51 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $8.4 |
| Trailing P/E Ratio | 35.63 |
| PEG Ratio | 2.17 |
| P/E Growth | 2.17 |
| Net Income | $3.25B |
| Net Margin | 13.21% |
| Pretax Margin | 18.20% |
| Return on Equity | 15.10% |
| Return on Assets | 7.21% |
Financials Score
| AltmanZ Score | 4.96 |
| Piotroski Score | 7.00 |
| Working Capital | 7.02B |
| Total Assets | 46.29B |
| Ebit | 4.92B |
| Market Cap | 126.42B |
| Total Liabilities | 23.31B |
Poll Results
About Stryker Corporation (NYSE:SYK) Stock
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care ... disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
Stryker: The Market Is Overreacting To One Disrupted Quarter
2026-07-09 09:18:39
Stryker remains a high-quality MedTech compounder despite a rare Q1 miss driven by a temporary cyber disruption. Q1 weakness was not demand-driven; full-year guidance is unchanged and end-market demand remains healthy. Current valuation reflects temporary disruption, offering a more attractive entry into SYK, though the stock is not cheap.
Beyond Automotive: Healthcare Automation Drives the Next Leg for Robotics ETFs
2026-07-08 15:05:24
Rising use of automation in healthcare is reshaping robotics ETFs as med-tech innovators gain prominence.
ICUI vs. SYK: Which Stock Should Value Investors Buy Now?
2026-07-08 12:41:12
Investors looking for stocks in the Medical - Products sector might want to consider either ICU Medical (ICUI) or Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
Stryker: Medtech On Sale, Benefiting From Industry Growth
2026-07-08 08:00:00
Stryker Corporation offers a compelling medtech investment, benefiting from robust industry growth and an innovation-led strategy. SYK trades at a 13% discount to fair value, with a forward P/E of 20.1 versus a 10-year average of 25.6. Consensus expects SYK's adjusted diluted EPS to compound at 11.2% annually through 2028, supporting high single-digit dividend growth.
Buy these quality, low-stress stocks for the summer, says Jefferies
2026-07-07 11:45:33
Markets have become more volatile as investors debate whether big tech companies are getting enough return on their AI spending. The S&P 500 momentum index has outperformed the wider market by more than 70% since 2024, close to levels seen during the 1990s dot-com era.
Stryker: The Reshaped Product Portfolio Will Drive Growth
2026-07-02 05:25:39
Stryker is a Dividend Aristocrat with 32 years of increases, robust cash flow, and a strong M&A-driven growth strategy. SYK's Q1 2026 results were impacted by a cybersecurity incident, but management maintained full-year guidance and expects normalization. The stock trades at ~21x 2026E EPS, below its 5-year average, suggesting undervaluation despite recent share price declines.
Stryker Vs. Intuitive Surgical: Stryker's Joint-Replacement Moat Over Intuitive's Premium Valuation
2026-07-01 11:14:31
Stryker (NYSE:SYK | SYK Price Prediction) and Intuitive Surgical (NASDAQ:ISRG) both closed the books on Q1 2026 with sharply different results.
Stryker to announce second quarter 2026 financial results
2026-07-01 08:00:00
Portage, Michigan, July 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) will host a webcast at 4:30 p.m. (Eastern time) on Thursday, July 30, 2026, to discuss its second quarter 2026 financial results.
Frequently Asked Questions
-
What is the current Stryker Corporation (SYK) stock price?
-
Stryker Corporation(NYSE:SYK) stock price is $311.07001 in the last trading session. During the trading session, SYK stock reached the peak price of $404.87 while $281 was the lowest point it dropped to. The percentage change in SYK stock occurred in the recent session was --6.15% while the dollar amount for the price change in SYK stock was -$-20.38.
-
SYK's industry and sector of operation?
-
The NYSE listed SYK is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of SYK?
-
Dragana Bunjevac | President of Eastern Europe, Middle East & Africa
J. Andrew Pierce | Group President of MedSurg & Neurotechnology
Jason Beach | VP and Group CFO of MedSurg & Neurotechnology
Kevin A. Lobo | Chairman & CEO
Preston Wells | Vice President & Chief Financial Officer -
How many employees does SYK have?
-
Number of SYK employees currently stands at 56000. SYK operates from 1941 Stryker Way, Portage, MI 49002, US.
-
Link for SYK official website?
-
Official Website of SYK is: https://www.stryker.com
-
How do I contact SYK?
-
SYK could be contacted at phone #269 385 2600 and can also be accessed through its website. SYK operates from 1941 Stryker Way, Portage, MI 49002, US.
-
How many shares of SYK are traded daily?
-
The average number of SYK shares traded daily for last 3 months was 2.7M.
-
What is the market cap of SYK currently?
-
The market value of SYK currently stands at $119.25B with its latest stock price at $311.07001